PremiumRatingsPrecision BioSciences: Strategic Focus on ARCUS Platform and Promising DMD Treatment Drives Buy Rating Precision BioSciences Reports Q1 2025 Financial Results Precision BioSciences Reports Q1 Results and Business Update PremiumThe FlyPrecision BioSciences receives FDA fast track designation for PBGENE-HBV Precision BioSciences: Strategic Developments and Promising Milestones Drive Buy Rating Promising Developments in Precision BioSciences’ Gene Editing Programs Drive Buy Rating PremiumThe FlyPrecision: Partner iECURE announced news from the OTC-HOPE study in January Precision BioSciences reports Q4 EPS ($2.22), consensus ($2.94) Precision BioSciences: Promising Gene Editing Advancements and Strategic Positioning in DMD and HBV Markets 
